OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Tawbi on the FDA Approval of Relatlimab/Nivolumab in Unresectable or Metastatic Melanoma

March 18th 2022

Hussein A. Tawbi, MD, PhD, discusses the FDA approval of relatlimab plus nivolumab in unresectable or metastatic melanoma.

Dr. Abid on the Efficacy of a Third COVID-19 Vaccine Dose After Hematopoietic Cell

March 17th 2022

Muhammad Bilal Abid, MD, MRCP, discusses the efficacy of a third COVID-19 vaccine dose after hematopoietic cell transplantation in patients with hematologic malignances.

Dr. Santos on the Utilization of Approved Monotherapies in NSCLC

March 17th 2022

Edgardo S. Santos, MD, FACP, discusses the utilization of approved monotherapies in non–small cell lung cancer.

Dr. Socinski on Treatment Considerations for Difficult-to-Treat Patients in Lung Cancer

March 17th 2022

Mark A. Socinski, MD, executive director, Thoracic Center, medical oncologist, AdventHealth Cancer Institute, discusses therapeutic considerations for difficult-to-treat patients in lung cancer.

Dr. Tagawa on Utilizing Bone-Targeting Radium-223 in Prostate Cancer

March 16th 2022

Scott T. Tagawa, MD, MS, FACP, discusses the use of radium-223 in prostate cancer.

Dr. Dreicer on the Impact of the CHAARTED Trial in mCSPC

March 16th 2022

Robert Dreicer, MD, discusses the impact of the phase 3 CHAARTED trial in metastatic castration-sensitive prostate cancer.

Dr. Sallman on the Role of Uproleselan in Targeting E-Selectin in AML

March 16th 2022

David Sallman, MD, discusses the role of uproleselan (GMI-1271) when utilized in acute myeloid leukemia.

Dr. Iacovelli on Next Steps of the ARIES Trial in Urothelial Cancer

March 15th 2022

Roberto Iacovelli, MD, PhD, discusses the potential next steps of the phase 2 ARIES trial in urothelial cancer.

Dr. Olawaiye on Front Line Treatment Sequencing Considerations in Ovarian Cancer

March 15th 2022

Alexander B. Olawaiye, MD, discusses front line treatment sequencing considerations in ovarian cancer.

Dr. Ansell on the Evolving Treatment Landscape in DLBCL

March 15th 2022

Stephen M. Ansell, MD, PhD, discusses the evolving treatment landscape in diffuse large B-cell lymphoma.

Inside the Clinic: JTCC Experts Share Strategies for When CAR T-Cell Therapy Is Not an Option

March 15th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, share strategies for when CAR T-cell therapy is not an option.

Inside the Clinic: JTCC Experts Discuss Approaches to CAR T-Cell Therapy

March 15th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss approaches to CAR T-cell therapy.

Dr. Bardia on the Rationale of Utilizing Endocrine Therapy in ER+ Breast Cancer

March 14th 2022

Aditya Bardia, MD, MPH, discusses the use of endocrine therapy in estrogen receptor–positive breast cancer.

Dr. Petrylak on the Rationale of the EV-103 Trial in MIBC

March 14th 2022

Daniel P. Petrylak, MD, discusses the rationale for of the phase 1b/2 EV-103 trial in patients with muscle-invasive bladder cancer.

Dr. Badani on the Evolution of Robotic Retroperitoneal Partial Nephrectomies in RCC

March 14th 2022

Ketan K. Badani, MD, discusses the evolution of robotic retroperitoneal partial nephrectomies in renal cell carcinoma.

Dr. Davidson on the Future of HER2-Targeted Therapies in Breast Cancer

March 14th 2022

Nancy E. Davidson, MD, discusses the future of HER2-targeted therapies in breast cancer.

Dr. Birrer on Remaining Questions in Platinum-Sensitive Ovarian Cancer

March 12th 2022

Michael J. Birrer, MD, PhD, discussed remaining questions when addressing platinum-sensitive ovarian cancer.

Dr. Olawaiye on the Social and Biological Determinants of Disparities in Women’s Cancer

March 12th 2022

Alexander B. Olawaiye, MD, discusses the social and biological determinants of disparities in women’s cancer.

Dr. Park on the Dosing Strategies Utilized in the FELIX Trial in R/R ALL

March 10th 2022

Jae Park, MD, discusses dosing strategies utilized in the phase 1/2 FELIX trial in relapsed/refractory acute lymphoblastic leukemia.

Dr. Roddie on the Potential Utilization of Obe-Cel in R/R ALL

March 10th 2022

Claire Roddie, MD, discusses the potential utilization of obecabtagene autoleucel in relapsed/refractory acute lymphoblastic leukemia.